No headlines found.
No press releases found.
No news found.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Kiora Pharmaceuticals trades on the NASDAQ stock market under the symbol KPRX.
As of May 1, 2026, KPRX stock price climbed to $2.44 with 280,267 million shares trading.
KPRX has a beta of 1.43, meaning it tends to be more sensitive to market movements. KPRX has a correlation of 0.13 to the broad based SPY ETF.
KPRX has a market cap of $10.71 million. This is considered a Sub-Micro Cap stock.
Last quarter Kiora Pharmaceuticals reported $0 in Revenue and -$1.60 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$1.06.
In the last 3 years, KPRX traded as high as $37.04 and as low as $1.76.
The top ETF exchange traded funds that KPRX belongs to (by Net Assets): VXF.
KPRX has underperformed the market in the last year with a price return of -25.7% while the SPY ETF gained +30.4%. KPRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +1.7% and -3.2%, respectively, while the SPY returned +4.4% and +1.5%, respectively.
KPRX support price is $2.23 and resistance is $2.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KPRX shares will trade within this expected range on the day.
